Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Pancreatic Neoplasms 6Glioblastoma 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Phase IB 1Ovarian Neoplasms 1Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1Mesonephric Gynecologic Cancer 1Melanoma 1Lung Neoplasms 1Low-Grade Serous Ovarian Cancer 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Endometrioid 1Brain Neoplasms 1Advanced Colorectal Cancer 1Adenocarcinoma of Lung 1

Interventions

Cisplatin 28Pemetrexed 24pembrolizumab 12Nivolumab 10Carboplatin 9atezolizumab 7Gemcitabine 7Cyclophosphamide 7durvalumab 6Drug Therapy 6sodium thiosulfate 5Radiotherapy, Intensity-Modulated 5tremelimumab 4aldesleukin 4Radiotherapy 4Interleukin-2 4sargramostim 3Vinorelbine 3Platinum 3Photochemotherapy 3Ipilimumab 3Doxorubicin 3Dihematoporphyrin Ether 3Chemotherapy, Adjuvant 3Cerebral Decortication 3vatalanib 2regorafenib 2niraparib 2lenvatinib 2cemiplimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Mesothelioma, Malignant × defactinib × Clear all
NCT04201145 2020-11-17

Pembrolizumab + Defactinib In Pleural Mesothelioma

Dana-Farber Cancer Institute

Phase 1 Withdrawn
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡